TL-895 and KRT-232 Study in Acute Myeloid Leukemia

• Status: Recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with KRT-232, a novel oral small molecule inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., having failed prior therapy) to be eligible for this study.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Telios Pharma, Inc.
• Collaborator: Kartos Therapeutics, Inc.

Criteria

Inclusion Criteria:

• TP53 wildtype AML

• Relapsed/Refractory to at least one prior therapy, one of which must have included a FLT-3 inhibitor

• FLT3 mutation (FLT3-TKD or FLT3-ITD)

• ECOG 0-2

• Adequate hematologic, hepatic, and renal functions

Exclusion Criteria:

• AML subtype 3

• Prior treatment with MDM2 antagonist therapies

• Eligible for HSCT